Btc Capital Management Has Increased Position in Cvs Health (CVS); Reinhart Partners Raised Stake in Gentex Com (GNTX) by $3.95 Million as Valuation Declined

October 20, 2017 - By Michael Collier

Btc Capital Management Inc increased its stake in Cvs Health Corp (CVS) by 15.48% based on its latest 2017Q2 regulatory filing with the SEC. Btc Capital Management Inc bought 12,986 shares as the company’s stock declined 4.23% while stock markets rallied. The institutional investor held 96,889 shares of the medical and nursing services company at the end of 2017Q2, valued at $7.80 million, up from 83,903 at the end of the previous reported quarter. Btc Capital Management Inc who had been investing in Cvs Health Corp for a number of months, seems to be bullish on the $77.76 billion market cap company. The stock rose 0.14% or $0.11 reaching $76.6 per share. About 9.03M shares traded or 40.65% up from the average. CVS Health Corp (NYSE:CVS) has declined 24.40% since October 20, 2016 and is downtrending. It has underperformed by 41.10% the S&P500.

Reinhart Partners Inc increased its stake in Gentex Corp Com (GNTX) by 18.53% based on its latest 2017Q2 regulatory filing with the SEC. Reinhart Partners Inc bought 219,621 shares as the company’s stock declined 8.68% while stock markets rallied. The institutional investor held 1.41M shares of the o.e.m. company at the end of 2017Q2, valued at $26.66M, up from 1.19M at the end of the previous reported quarter. Reinhart Partners Inc who had been investing in Gentex Corp Com for a number of months, seems to be bullish on the $5.53 billion market cap company. The stock rose 0.55% or $0.11 reaching $19.49 per share. About 6.02 million shares traded or 278.62% up from the average. Gentex Corporation (NASDAQ:GNTX) has risen 19.63% since October 20, 2016 and is uptrending. It has outperformed by 2.93% the S&P500.

Since June 1, 2017, it had 0 buys, and 1 sale for $192,155 activity.

More recent Gentex Corporation (NASDAQ:GNTX) news were published by: Seekingalpha.com which released: “Gentex’s (GNTX) Q3 2017 Results – Earnings Call Transcript” on October 20, 2017. Also Nasdaq.com published the news titled: “Gentex Corporation (GNTX) Ex-Dividend Date Scheduled for October 05, 2017” on October 04, 2017. Globenewswire.com‘s news article titled: “Gentex Reports Third Quarter 2017 Financial Results” with publication date: October 20, 2017 was also an interesting one.

Reinhart Partners Inc, which manages about $4.85 billion and $1.00 billion US Long portfolio, decreased its stake in Nisource Inc (NYSE:NI) by 131,030 shares to 837,062 shares, valued at $21.23 million in 2017Q2, according to the filing. It also reduced its holding in Jones Lang Lasalle Inc Com (NYSE:JLL) by 39,567 shares in the quarter, leaving it with 236,009 shares, and cut its stake in Fifth Third Bancorp Com (NASDAQ:FITB).

Among 6 analysts covering Gentex Corp (NASDAQ:GNTX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Gentex Corp had 11 analyst reports since October 20, 2015 according to SRatingsIntel. Robert W. Baird downgraded the stock to “Neutral” rating in Wednesday, January 27 report. The stock of Gentex Corporation (NASDAQ:GNTX) earned “Outperform” rating by Robert W. Baird on Thursday, August 24. The firm earned “Neutral” rating on Monday, December 19 by Susquehanna. Craig Hallum downgraded the stock to “Hold” rating in Monday, July 24 report. The stock of Gentex Corporation (NASDAQ:GNTX) has “Outperform” rating given on Friday, October 21 by FBR Capital. The stock of Gentex Corporation (NASDAQ:GNTX) has “Buy” rating given on Wednesday, August 23 by KeyBanc Capital Markets. The stock of Gentex Corporation (NASDAQ:GNTX) has “Buy” rating given on Wednesday, July 19 by FBR Capital. KeyBanc Capital Markets maintained Gentex Corporation (NASDAQ:GNTX) on Thursday, October 12 with “Buy” rating.

Investors sentiment increased to 0.92 in 2017 Q2. Its up 0.07, from 0.85 in 2017Q1. It is positive, as 42 investors sold GNTX shares while 139 reduced holdings. 47 funds opened positions while 120 raised stakes. 226.47 million shares or 2.40% less from 232.03 million shares in 2017Q1 were reported. Hancock has invested 0.08% in Gentex Corporation (NASDAQ:GNTX). Moreover, James Investment Rech Inc has 0.01% invested in Gentex Corporation (NASDAQ:GNTX). Clearbridge Limited Liability invested in 694,916 shares or 0.28% of the stock. Hsbc Public Limited Liability Corp holds 226,522 shares. Creative Planning reported 21,559 shares. Credit Agricole S A invested in 84,304 shares or 0.01% of the stock. Goldman Sachs Grp Inc owns 0.01% invested in Gentex Corporation (NASDAQ:GNTX) for 2.14M shares. Victory Cap Mngmt, Ohio-based fund reported 73,537 shares. Zebra Cap Management Ltd Liability Corporation stated it has 0.52% of its portfolio in Gentex Corporation (NASDAQ:GNTX). Nomura Holding reported 0% in Gentex Corporation (NASDAQ:GNTX). Commonwealth Equity Services holds 46,936 shares. Scharf Invs Ltd Liability accumulated 2.71% or 6.08 million shares. Goelzer Investment Mgmt Inc accumulated 0.58% or 250,294 shares. North Star Investment holds 0% or 107 shares. 1,040 are held by Qci Asset Management Ny.

More notable recent CVS Health Corp (NYSE:CVS) news were published by: Nasdaq.com which released: “First PREMIER Bank Buys CVS Health Corp, Vanguard Total Bond Market, Capital …” on October 14, 2017, also Seekingalpha.com with their article: “CVS: Whatever Floats Your Moat” published on October 16, 2017, Marketwatch.com published: “Anthem to launch own pharmacy-benefits manager, partner with CVS Health” on October 18, 2017. More interesting news about CVS Health Corp (NYSE:CVS) were released by: Investorplace.com and their article: “It’s Time to Profit From CVS Health Corp (CVS) Stock’s “Amazonian Flu”” published on October 10, 2017 as well as Fool.com‘s news article titled: “Better Buy: CVS Health Corporation vs. Walgreens Boots Alliance” with publication date: October 12, 2017.

Since June 12, 2017, it had 0 buys, and 1 sale for $18.44 million activity.

Among 24 analysts covering CVS Health (NYSE:CVS), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. CVS Health had 44 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Hold” rating by Wolfe Research on Wednesday, August 16. Oppenheimer maintained the shares of CVS in report on Thursday, December 17 with “Outperform” rating. The firm has “Buy” rating given on Wednesday, November 9 by Mizuho. The company was maintained on Friday, October 13 by SunTrust. The firm has “Outperform” rating by Oppenheimer given on Friday, August 28. The firm has “Neutral” rating given on Thursday, December 17 by Goldman Sachs. Needham maintained the shares of CVS in report on Friday, September 8 with “Hold” rating. Morgan Stanley downgraded it to “Equal-Weight” rating and $104 target in Monday, June 20 report. Deutsche Bank maintained the shares of CVS in report on Thursday, August 20 with “Hold” rating. The rating was maintained by S&P Research with “Strong Buy” on Monday, November 2.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.